Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Group Team
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • preCISIONTM
    • Affimer®
    • Pipeline
    • Partners
    • Clinical trials
    • Team
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • Team
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

News

20 Oct 2022

Admission of the Company’s Ordinary Shares

Investors
20 Oct 2022

Posting of the Company’s Open Offer Circular

Investors
18 Oct 2022

Result of placing

Investors
18 Oct 2022

Proposed placing, open offer and issue of convertible bonds

Diagnostics | Investors
18 Oct 2022

Proposed acquisition of Launch Diagnostics

Diagnostics | Investors
29 Sep 2022

Interim Results for the Period Ended 30 June 2022

Investors
26 Sep 2022

Notice of Results

Investors
05 Sep 2022

AVA6000 receives Orphan Drug Designation from the US Food and Drug Administration

Investors | Therapeutics
01 Sep 2022

Phase I clinical study of AVA6000 to advance to the fourth cohort

Investors | Therapeutics
21 Jul 2022

AffyXell Successfully Completes Funding Round

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2023 Avacta Life Sciences Limited. Registered company no. 06605196.